Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Windtree Therapeutics stock | $5.94

Own Windtree Therapeutics stock in just a few minutes.

Fact checked

Windtree Therapeutics, Inc is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars. Windtree Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of USD$105.1 million.

How to buy shares in Windtree Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Windtree Therapeutics. Find the stock by name or ticker symbol: WINT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Windtree Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.94, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Windtree Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Windtree Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Windtree Therapeutics share price

Use our graph to track the performance of WINT stocks over time.

Windtree Therapeutics shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$5.94
52-week rangeUSD$3.05 - USD$44.91
50-day moving average USD$6.6368
200-day moving average USD$7.138
Wall St. target priceUSD$12.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.134

Buy Windtree Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Windtree Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Windtree Therapeutics price performance over time

Historical closes compared with the close of $5.94 from 2020-12-09

1 week (2021-01-12) N/A
1 month (2020-12-23) 12.29%
3 months (2020-10-19) N/A
6 months (2020-07-19) N/A
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Windtree Therapeutics financials

Gross profit TTM USD$-12,489,000
Return on assets TTM -15.41%
Return on equity TTM -50.45%
Profit margin 0%
Book value $4.475
Market capitalisation USD$105.1 million

TTM: trailing 12 months

Shorting Windtree Therapeutics shares

There are currently 119,333 Windtree Therapeutics shares held short by investors – that's known as Windtree Therapeutics's "short interest". This figure is 21.8% down from 152,579 last month.

There are a few different ways that this level of interest in shorting Windtree Therapeutics shares can be evaluated.

Windtree Therapeutics's "short interest ratio" (SIR)

Windtree Therapeutics's "short interest ratio" (SIR) is the quantity of Windtree Therapeutics shares currently shorted divided by the average quantity of Windtree Therapeutics shares traded daily (recently around 15067.297979798). Windtree Therapeutics's SIR currently stands at 7.92. In other words for every 100,000 Windtree Therapeutics shares traded daily on the market, roughly 7920 shares are currently held short.

However Windtree Therapeutics's short interest can also be evaluated against the total number of Windtree Therapeutics shares, or, against the total number of tradable Windtree Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Windtree Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Windtree Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0165% of the tradable shares (for every 100,000 tradable Windtree Therapeutics shares, roughly 17 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Windtree Therapeutics.

Find out more about how you can short Windtree Therapeutics stock.

Windtree Therapeutics share dividends

We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.

Have Windtree Therapeutics's shares ever split?

Windtree Therapeutics's shares were split on a 1:3 basis on 29 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.

Windtree Therapeutics share price volatility

Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $3.05 up to $44.91. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is 0.1122. This would suggest that Windtree Therapeutics's shares are less volatile than average (for this exchange).

Windtree Therapeutics overview

Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site